A beta version of life: p110β takes center stage.

Hashem A. Dbouk, Jonathan M. Backer

Research output: Contribution to journalReview article

34 Scopus citations

Abstract

The PI3K pathway is frequently activated in tumors, most commonly through p110α mutation or PTEN deletion. In contrast to p110α, p110β is oncogenic when over-expressed in the wild-type state, suggesting that its regulation by p85 is different than that of p110α. In this perspective, we summarize recent data concerning the regulation of p110β, which shows that wild-type p110β acts like an oncogenic mutant of p110α. We also discuss the significance of this altered regulation in tumor models of PTEN deletion, as well as the potential implications of the unique p110β regulation on GPCR-driven tumorigenesis.

Original languageEnglish (US)
Pages (from-to)729-733
Number of pages5
JournalOncotarget
Volume1
Issue number8
DOIs
StatePublished - Dec 2010
Externally publishedYes

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'A beta version of life: p110β takes center stage.'. Together they form a unique fingerprint.

  • Cite this